Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.62 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.62 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | ALPL | P05186 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563112 | 0.89 | NPC1 (0.56) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL9525840 | 0.81 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL30118936 | 0.81 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL28871828 | 0.81 | GAA (0.60) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL1147702 | 0.80 | KDM4E (0.73) | RAB9ANPC1SMN1; SMN2PKMHPGD | |
| SCHEMBL6450640 | 0.80 | KDM4E (0.60) | RAB9ANPC1SMN1; SMN2PKMHPGD | |
| SCHEMBL27178187 | 0.80 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL27178180 | 0.80 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL29510900 | 0.79 | MEN1 (0.68) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL4651584 | 0.79 | MEN1 (0.68) | RAB9ANPC1SMN1; SMN2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | RAB9A 2483/4885NPC1 59/4885SMN1; SMN2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.